Greg Fine, Co-chair of the Private Equity Practice, is well-versed in guiding funds and companies through middle market and mega deals in the technology, manufacturing, healthcare, life sciences, and energy sectors. He focuses on representing private equity funds, family offices and their portfolio companies in complex acquisitions, divestitures, recapitalizations, restructurings and “shared-control” deals. Greg brings a commercial, pragmatic and solutions-oriented perspective to his client’s transactions.
Prior to rejoining Mintz in 2012, Greg was an attorney at another Boston-based law firm. There, he represented private equity sponsors and publicly and privately held companies in corporate transactional matters.
Greg Fine, Co-chair of the Private Equity Practice, is well-versed in guiding funds and companies through middle market and mega deals in the technology, manufacturing, healthcare, life sciences, and energy sectors. He focuses on representing private equity funds, family offices and their portfolio companies in complex acquisitions, divestitures, recapitalizations, restructurings and “shared-control” deals. Greg brings a commercial, pragmatic and solutions-oriented perspective to his client’s transactions.
Experience
- Represented a fund in its $1.1 billion leveraged buyout of a construction manufacturer of bridge, drainage, earth stabilization, and stormwater solutions
- Represented a fund in its $223 million sale of a specialized large-scale bakery to another fund
- Represented a fund in its leveraged buyout of a global supplier of mobile audio/video accessories, installation and fabrication supplies, and OEM integration solutions
- Represented a fund in its leveraged buyout of a manufacturer of custom engineered protective covers, truck roll-up doors, and cable/hose carriers
- Represented a fund in its leveraged buyout of a manufacturer and fabricator of custom hose, conveyor belt, sealing/safety products with operations in the US and Canada
- Represented a fund in its sale of a cement, ready mix concrete, aggregate, asphalt production company to a large strategic acquirer
- Represented a health care-focused fund in its $130 million leveraged buyout of a wound company
- Represented a large fund in its $550 million sale of a large-scale dialysis company to another private equity company
- Represented a health care-focused private equity company in its $330 million leveraged buyout of two clinical medical laboratories
- Represented one of Europe’s leading independent music publishers in its $250 million acquisition of a well-renowned Broadway-based administrator and promoter of entertainment copyrights as well as the rights to the songs and musicals of certain legendary Broadway songwriters
- Represented a private equity company in its $23 million leveraged buyout of a restaurant chain
- Represented a private equity sponsor in the $70 million leveraged buyout of a hair care company
- Represented a portfolio company of a large private equity sponsor in the acquisition of a drug development company, with contingent consideration, based on success of the product, up to $400 million
viewpoints
2025 Private Equity Trends Outlook
November 19, 2024 | Blog | By Gregory Fine, Kari Harris, Kurt Steinkrauss
Learn more about important trends in 2025 for the private equity landscape, including the expansion of continuation vehicles as a vital liquidity tool, heightened regulatory scrutiny and antitrust pressures introducing both challenges and opportunities, and interest rate cuts and evolving buyer-seller risk tolerance creating a more complex deal environment.
Survival of Reps and Warranties: Survival of Reps and Warranties: Avoiding Unpleasant Surprises for Buyers
May 16, 2014 | Alert | By Gregory Fine, Jessica Mendoza
News & Press
Mintz Advises Charlesbank Capital Partners on Strategic Investment with IMPLAN Group
November 18, 2024
Mintz advised Charlesbank Capital Partners (“Charlesbank”), a middle-market private equity firm with more than $22 billion in total assets, on a strategic investment with IMPLAN Group LLC (“IMPLAN”), a leading provider of economic impact data and analytical software.
Private Equity Co-chair Gregory Fine spoke to S&P Global about the increased number of earnout provisions in M&A when the seller is a private equity firm.
Mintz’s Private Equity Practice Appoints New Leadership
November 17, 2022
Mintz has appointed Members Gregory Fine and Matthew T. Simpson to co-lead the Private Equity practice alongside current chair, Kurt Steinkrauss. The change is effective immediately.
Mintz Names New Leaders In Private Equity
November 17, 2022
Members Gregory Fine, Matthew T. Simpson and Kurt Steinkrauss were featured in an article published by The Deal highlighting their appointment to co-lead the Firm's Private Equity practice.
Mintz Leads On A Quartet of Back-To-Back Private Equity Closings
October 25, 2022
Mintz attorneys in Boston, New York, and Washington, DC, closed four Private Equity transactions in the past month. Along with acquisitions for Charlesbank Capital Partners, DIF Capital Partners portfolio company Joink LLC, and Artemis Capital Partners, the firm represented the CEO and some managers of Salary.com in the sale of most of the company’s equity interests to Accel-KKR.
Mintz Takes Lead For Med-Pharmex In Its Sale To Britain’s Dechra
August 31, 2022
Mintz completed a deal as counsel to Med-Pharmex in its sale to British-owned veterinary products developer and manufacturer Dechra Pharmaceuticals. Through the sale, Dechra will gain further access and nearly 40 years of experience in the U.S. veterinary health market.
Mintz Advised Capstone Partners in Sale to Huntington
March 01, 2022
Mintz Advises DW Healthcare Partners in Sale of Prime Education
August 29, 2018
The M&A Advisor Recognizes Mintz Transaction as $50 - 100 Million "Cross Border Deal of the Year"
June 05, 2018
Mintz Represents Right Networks in Sale of Controlling Interest to BV Investment Partners
October 11, 2016
Events & Speaking
Visiting Lecturer, Transactional Law Workshop – Mergers and Acquisitions, Harvard Law School (January 2024)
Harvard Law School
Greg Fine, Co-chair of the Private Equity Practice, is well-versed in guiding funds and companies through middle market and mega deals in the technology, manufacturing, healthcare, life sciences, and energy sectors. He focuses on representing private equity funds, family offices and their portfolio companies in complex acquisitions, divestitures, recapitalizations, restructurings and “shared-control” deals. Greg brings a commercial, pragmatic and solutions-oriented perspective to his client’s transactions.
Recognition & Awards
Senior editor of Boston College Law Review
Order of the Coif
Recent Insights
2025 Private Equity Trends Outlook
November 19, 2024| Blog|
Mintz advised Charlesbank Capital Partners (“Charlesbank”), a middle-market private equity firm with more than $22 billion in total assets, on a strategic investment with IMPLAN Group LLC (“IMPLAN”), a leading provider of economic impact data and analytical software.
Private Equity Co-chair Gregory Fine spoke to S&P Global about the increased number of earnout provisions in M&A when the seller is a private equity firm.
